NIH Supports New In Vivo CAR‑T Strategy via Lipid Nanoparticles

Published on NIH Research Matters

NIH-funded researchers led by Capstan Therapeutics and the University of Pennsylvania have devised a method to engineer CAR‑T cells inside the body using targeted lipid nanoparticles. These nanoparticles are designed to deliver CAR instructions to T cells in living organisms, bypassing complex ex vivo manufacturing. In preclinical trials, treated mice showed significant tumor reduction and primates experienced rapid but reversible B‑cell depletion, suggesting a safer, more scalable path for both cancer and autoimmune therapies.

Read the full article on NIH Research Matters:

👉 Engineering immune cells within the body

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.